- Home
- EXEL vs NIO Comparison
EXEL vs NIO Comparison
Compare EXEL & NIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- NIO
- Stock Information
- Founded
- EXEL 1994
- NIO 2014
- Country
- EXEL United States
- NIO China
- Employees
- EXEL N/A
- NIO N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- NIO Auto Manufacturing
- Sector
- EXEL Health Care
- NIO Consumer Discretionary
- Exchange
- EXEL Nasdaq
- NIO Nasdaq
- Market Cap
- EXEL 9.4B
- NIO 9.3B
- IPO Year
- EXEL 2000
- NIO 2018
- Fundamental
- Price
- EXEL $36.85
- NIO $4.45
- Analyst Decision
- EXEL Buy
- NIO Hold
- Analyst Count
- EXEL 18
- NIO 11
- Target Price
- EXEL $37.24
- NIO $6.02
- AVG Volume (30 Days)
- EXEL 2.5M
- NIO 49.1M
- Earning Date
- EXEL 02-11-2025
- NIO 03-04-2025
- Dividend Yield
- EXEL N/A
- NIO N/A
- EPS Growth
- EXEL 170.77
- NIO N/A
- EPS
- EXEL 1.76
- NIO N/A
- Revenue
- EXEL $2,168,701,000.00
- NIO $9,000,115,178.00
- Revenue This Year
- EXEL $5.36
- NIO $23.54
- Revenue Next Year
- EXEL $10.59
- NIO $48.32
- P/E Ratio
- EXEL $20.87
- NIO N/A
- Revenue Growth
- EXEL 18.49
- NIO 15.67
- 52 Week Low
- EXEL $20.14
- NIO $3.61
- 52 Week High
- EXEL $37.59
- NIO $7.71
- Technical
- Relative Strength Index (RSI)
- EXEL 65.59
- NIO 54.27
- Support Level
- EXEL $34.01
- NIO $4.30
- Resistance Level
- EXEL $35.46
- NIO $4.55
- Average True Range (ATR)
- EXEL 1.09
- NIO 0.17
- MACD
- EXEL 0.36
- NIO 0.03
- Stochastic Oscillator
- EXEL 95.70
- NIO 62.88
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold over 160,000 EVs in 2023, accounting for about 2% of the China passenger new energy vehicle market.